BioSpace News Archive

AbbVie (NYSE: ABBV), today announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of statistically significant improvement of overall survival (OS) and composite complete remission rate (CR + CRi) for patients with previously-untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy

BrainsWay Ltd. today reported financial results for the quarter and full-year ended December 31, 2019, and provided an operational update. “We are very pleased with our solid fourth quarter and full-year 2019 results. Our strong results are indicative of the continued growing demand for our deep transcranial ma

- Leading dermatologist, Dr. Elizabeth Tanzi, to present pivotal cellulite trial results -

In recognition of the essential role CVS Health employees are playing as the country faces the COVID-19 pandemic, the company is awarding bonuses to employees who are required to be at CVS facilities to assist patients and customers in this time of unprecedented need.

The Anesthesia Patient Safety Foundation and the Patient Safety Movement Foundation are proud to announce that Brian Bensadigh, MD, MBA of the Keck School of Medicine of USC, has been awarded the 2020 Patient Safety Curriculum Award.

ndivior PLC (LON: INDV) today announced the publication of one-year outcomes from a 24-month real-world observational study, RECOVER™ (Remission from Chronic Opioid Use—Studying Environmental and Socio-Economic Factors on Recovery).

The company’s platform continues to help veterinarians maintain continuity of care for their pet and horse owner clients during this crisis

Phase III VIALE-A study showed Venclexta plus azacitidine helped people with the most common type of aggressive leukemia in adults live longer compared to azacitidine alone – – Data will be shared with global health authorities and presented at an upcoming medical meeting – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III VIALE-A study met

Genprex, Inc. today announced the appointment of Catherine M. Vaczy as Executive Vice President and Chief

Medexus Pharmaceuticals Inc. today provided an update to its shareholders reaffirming the strength of its business and outlining the measures it has taken in light of the COVID-19 healthcare crisis. Since December 31, 2019, the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency mea